UnknownPhase 4

Low-dose Aspirin Therapy in Patients With Ischemic Stroke and Microbleeds

China400 participantsStarted 2020-10-01

Plain-language summary

The purpose of this study is to investigate the safety and efficacy of low-dose (50mg) aspirin as a secondary prevention drug in patients with Non-Cardioembolic Ischemic Stroke accompanied by cerebral microbleeds.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with cerebral infarction diagnosed clinically as non-cardioembolic ischemic stroke;
✓. Age ≥ 18 years;
✓. Onset time ≤ 3 weeks;
✓. At least one cerebral microbleeds lesion was found on SWI;
✓. Informed consent was signed.

Exclusion criteria

✕. Patients with symptomatic intracranial hemorrhage;
✕. No microbleeds or bleeding lesion \> 10 mm was found on SWI;
✕. Vascular malformations, tumors, abscesses or other major non ischemic brain diseases were present;
✕. Clear anticoagulant indications (such as atrial fibrillation);
✕. There are contraindications for aspirin use;
✕. The focus of microbleeds is limited to the cortex or other evidence suggests that the patient has cerebral amyloid angiopathy;
✕. Patients with coronary heart disease or other diseases need to take antiplatelet drugs;
✕. Serious systemic diseases;

What they're measuring

Increase of cerebral microbleeds

Timeframe: 6 months after onset

Trial details

NCT IDNCT04504864

SponsorXijing Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-02

Contact for this trial

Wen Jiang, Ph.D

86-029-84771319 jiangwen@fmmu.edu.cn

View on ClinicalTrials.gov More Ischemic Stroke trials